ejpmr, 2024, 12(1), 85-91

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

AN OVERVIEW ON ROLE OF AI IN DRUG DISCOVERY

Nehal Shrivastava, Shristi Raikwar, Shubham Chilore, Puja Kumari*, Nirmal Dongre and Raghvendra Dubey

Institute of Pharmaceutical Sciences, SAGE University, Indore.

***Corresponding Author: Puja Kumari**

Institute of Pharmaceutical Sciences, SAGE University, Indore.

Article Received on 29/10/2024 **Article Revised on 20/11/2024** **Article Accepted on 10/12/2024**

ABSTRACT

One of the most popular sectors in the tech and healthcare industries right now is artificial intelligence. In the search and development of new drugs, artificial intelligence is essential. Drug design using computer-assisted design (CADD) has supplanted the traditional approach. Artificial intelligence is assisting businesses in the development of new drugs in a faster, more affordable, and more efficient manner, saving money and manpower in the process of creating new drug molecules to treat any disease. Quantitative structure-activity relationship (QSAR) analysis, activity scoring, in silico testing, biomarker development, and mode of action identification are all aided by artificial intelligence. It is revolutionizing these sectors by swiftly identifying potential drug candidates, efficiently conducting clinical trials, and customizing patient care. AI optimizes drug manufacturing processes, augments safety monitoring, and streamlines market analysis. In clinical trials, AI streamlines patient recruitment and ensures more precise trial designs, leading to faster and more efficient research. AI empowers personalized medicine by tailoring treatment plans and drug dosages to individual patient characteristics. AI also optimizes pharmaceutical manufacturing processes, amplifies safety monitoring by analyzing real-time data for adverse events, and supports market analysis and sales strategies. AI in the pharmaceutical industry is a multifaceted tool. Artificial Intelligence (AI) has the potential to streamline complex pharmaceutical regulatory matters. Regulatory processes like audits and dossier completion can be automated with AI tools.

INTRODUCTION

The use of artificial intelligence (AI) in medicinal chemistry has gained significant attention in recent years as a potential means of revolutionizing the pharmaceutical industry. Drug discovery, the process of identifying and developing new medications, is a complex and time consuming endeavor that traditionally relies on labor-intensive techniques such as trial-ander or experimentation and high-throughput screening. However, AI techniques such as machine learning (ML) and natural language processing offer the potential to accelerate and improve this process by enabling more efficient and accurate analysis of large amounts of data. The successful use of deep learning (DL) to predict the efficacy of drug compounds with high accuracy has been recently described. AI-based methods have also been able to predict the toxicity of drug candidates. These and other research efforts have highlighted the capacity of AI to improve the efficiency and effectiveness of drug discovery processes.

The goal of artificial intelligence (AI) technologies is to give machines the ability to process information, adapt to various environments, and make decisions or take actions that resemble human intelligence. Throughout the drug discovery and development process, artificial intelligence has revolutionized multiple steps and made significant strides in the field of pharmaceutical drug development. The use of AI in the creation of pharmaceutical drugs is summarized as follows:

- **Target Identification and Validation**

AI analyzes biological information, such as genetics, proteomics, and scientific literature, to identify potential drug targets. Machine learning models help prioritize and validate these targets, increasing the chances of success in later stages.

- **Drug Design and Discovery**

AI-driven drug design accelerates the development of novel compounds with desired properties. Generative adversarial networks (GANs) and deep learning are used to design molecules and predict their interactions with target proteins. Virtual screening, powered by AI, efficiently identifies potential drug candidates from vast chemical libraries.

- **AI in Target Identification and Validation**

The first step in drug discovery is to identify a biological target associated with a disease. AI can help in this critical stage by analyzing large datasets from genomics, proteomics, and other biological research to pinpoint potential targets more accurately. AI models, particularly deep learning algorithms, can mine vast datasets such as gene expression profiles, mutation databases, and

scientific literature to uncover new insights about disease mechanisms. By applying natural language processing (NLP) to analyze biomedical literature, AI can assist researchers in identifying relevant molecular pathways, proteins, and genes that may serve as drug targets. Additionally, AI models can predict the relevance and druggability of targets—i.e., whether a compound can effectively bind to the target and exert therapeutic effects—by simulating molecular interactions. This capability reduces the time spent on experimental validation and helps prioritize targets with the highest potential.

➢ **AI in Drug Screening and Hit Discovery**

Once potential targets are identified, the next step is finding compounds that can interact with these targets. This is traditionally done through high-throughput screening (HTS), where millions of compounds are tested for biological activity. However, HTS is expensive and time-consuming. AI has the potential to revolutionize this process by utilizing machine learning (ML) algorithms to predict how chemical compounds will interact with biological targets. These models are trained on existing data from chemical libraries, including known interactions between molecules and biological targets. Using techniques like virtual screening, AI can identify promising drug candidates much more efficiently than traditional methods, without needing to physically test every compound.

➢ **AI in Drug Optimization and Design**

Once a promising drug candidate is identified, the next task is to optimize its properties, such as potency, stability, and selectivity. AI can help improve the drug's characteristics by leveraging advanced algorithms to model molecular interactions, predict side effects, and even design new molecules with better efficacy. Generative models like generative adversarial networks (GANs) and reinforcement learning are increasingly being used to design novel drug-like compounds. These AI techniques can explore vast chemical spaces to propose new molecular structures that might not have been considered by human researchers. This can lead to the discovery of innovative therapeutic agents that would otherwise be difficult to identify through traditional methods. Additionally, AI is particularly useful in the optimization of pharmacokinetic properties and the reduction of off-target effects—helping to develop drugs that are more effective with fewer side effects.

➢ **AI in Clinical Trials**

Clinical trials are one of the most time-consuming and expensive parts of drug development, often failing due to issues like patient recruitment, ineffective trial designs, or adverse reactions. AI is being leveraged to improve clinical trial design, patient recruitment, and monitoring.

- **Patient Recruitment**: AI can analyze electronic health records (EHRs) to identify patients who meet the specific criteria for a clinical trial, speeding up recruitment and ensuring a more diverse patient population.
- **Trial Design:** Machine learning algorithms can predict which drug regimens are most likely to succeed in clinical trials, allowing for more efficient and targeted trial designs. These models can also help in adaptive trials, where the treatment protocol can be adjusted in real time based on the interim results.
- **Monitoring and Safety**: AI can track patient responses to treatment more effectively, flagging potential adverse events early, allowing for quicker interventions. This enhances patient safety and minimizes the risk of late-stage trial failures.

➢ **AI in Drug Repurposing**

Drug repurposing, or the process of finding new uses for existing drugs, is another area where AI is having a significant impact. AI can quickly analyze vast datasets of approved drugs and their known mechanisms to identify potential candidates for repurposing in the treatment of other diseases. This can significantly reduce the time and cost of drug development, as many of the safety and pharmacokinetic data are already available for existing drugs. AI models, using techniques such as NLP and graph-based analysis, can identify hidden relationships between diseases, genes, and drugs, uncovering new therapeutic opportunities. This approach has already shown promise in the context of rare diseases and conditions like cancer, where AI has identified drugs that may be effective but were previously overlooked.

➢ **The role of collaboration between AI researchers and pharmaceutical scientists**

The role of collaboration between AI researchers and pharmaceutical scientists is crucial in the development of innovative and effective treatments for various diseases. By combining their expertise and knowledge, they can create powerful algorithms and machine learning models aimed to predict the efficacy of potential drug candidates and speed up the drug discovery process. This collaboration can also help improve the accuracy and efficiency of clinical trials, as AI algorithms can be used to analyze the data collected during these trials to identify trends and potential adverse effects of the drugs being tested. This can help pharmaceutical companies make informed decisions about which drug candidates to pursue and can speed up the overall drug development process. Furthermore, collaboration between AI researchers and pharmaceutical scientists can also help improve the accessibility and affordability of healthcare. By using AI algorithms to analyze data from large populations, they can identify trends and patterns that can help predict the effectiveness of potential drug candidates for specific patient populations, which can help tailor treatments to the needs of individual patients. An illustrative example is the collaboration between the pharmaceutical company Merck and the AI company Numerate to develop AI-based approaches for medicinal chemistry. Many new companies are currently arising around this area and their impact is expected to be

significant at the short term. By working together, they can help to identify new targets for drug development and improve the effectiveness of existing treatments, ultimately benefiting patients and improving their quality of life.

- **AI networks and tools**

AI comprises a number of approach domains, including machine learning (ML), a fundamental paradigm, reasoning, knowledge representation, and solution search. In machine learning (ML), algorithms are used to find patterns in a set of data that has been further categorised. Deep learning (DL), a branch of machine learning that uses artificial neural networks (ANNs), is one such branch. These are a collection of intricately connected computing components that simulate the electrical impulse transmission in the human brain by using perceptions that are similar to biological human neurons. RNNs, like Boltzmann constants and Hopfield networks, are closed loop networks with the ability to memorize and store information. CNNs are a group of dynamic systems with local connections that are identified by their topology and used for a variety of tasks, including pattern recognition, advanced signal processing, modeling biological systems, processing complex brain operations, and image and video processing. Kohonen networks, RBF networks, LVQ networks, counter-propagation networks, and ADALINE networks are some of the most intricate varieties. The networks that make up the fundamental architecture of AI systems have formed the basis for the development of several technologies. The International Business Machine (IBM) Watson supercomputer (IBM, New York, USA) is one such instrument created utilizing AI technology. It was created to help with the study of a patient's medical data and its association with a sizable database, ultimately leading to the suggestion of cancer treatment options. The quick diagnosis of illnesses is another application for this technique.



➢ **Resources and methods for AI-based drug discovery**

Data resources, data representation schemes, and AI methods are the three key components of applying AI to drug discovery.



➢ **Application of AI in Drug Repurposing**

Drug repurposing, sometimes referred to as drug repositioning or drug reprofiling, is a technique used in pharmaceutical research and development wherein approved medications that were first created to treat a single illness are examined to see if they can also be used to treat other ailments. This approach is gaining prominence in the pharmaceutical industry because it offers several advantages

➢ **Cost-efficiency**

It is expensive and time-consuming to create a new medication from the ground up. Because most of the necessary research has already been done, repurposing existing drugs can save a great deal of time and money.

➢ **Safety**

Existing drugs have often undergone extensive safety testing, which means that their potential side effects and safety profiles are well-understood. This can expedite the approval process for new indications.

➢ **Pharmacokinetics**

The pharmacokinetics of known drugs, including how they are absorbed, distributed, metabolized, and excreted by the body, is well-documented. This knowledge is valuable for repurposing efforts.

➢ **Expanded Indications**

Repurposing can lead to new therapeutic uses for drugs, extending their lifespan and profitability.

➢ **Rare Diseases**

Drug repurposing can make otherwise unprofitable drugs viable for treating rare diseases, as pharmaceutical companies may not invest in developing new drugs for these conditions.

➢ **Drug Combinations**

Existing drugs can be repurposed in combination with one another or with new drugs to enhance treatment efficacy.



➢ **Challenges and Future Outlook**

Despite its many advantages, the integration of AI in drug discovery also faces several challenges. One of the main hurdles is the quality and accessibility of data. AI models require large, high-quality datasets to train effectively, and in many cases, proprietary data or incomplete datasets can limit the model's accuracy. Furthermore, the "black-box" nature of many AI algorithms can make it difficult for researchers to fully understand how predictions are made, raising concerns around transparency and interpretability. Despite these challenges, the future of AI in drug discovery looks incredibly promising. As AI technology continues to evolve, and as datasets become more comprehensive and standardized, AI's role in drug development is expected to grow exponentially. The combination of AI's computational power with human expertise has the potential to unlock a new era of precision medicine, where drugs are developed faster, more efficiently, and with a greater understanding of their effects on individual patients.

➢ CONCLUSION

In conclusion, AI has the potential to revolutionize the drug discovery process, offering improved efficiency and accuracy, accelerated drug development, and the capacity for the development of more effective and personalized treatments. However, the successful application of AI in drug discovery is dependent on the availability of high-quality data, the addressing of ethical concerns, and the recognition of the limitations of AI-based approaches. Recent developments in AI, including the use of data augmentation, explainable AI, and the integration of AI with traditional experimental methods, offer promising strategies for overcoming the challenges and limitations of AI in drug discovery. The growing interest and attention from researchers, pharmaceutical companies, and regulatory agencies, combined with the potential benefits of AI, make it an exciting and promising area of research, with the potential to transform the drug discovery process.

➢ REFRENCES

1. Paul, D. et al. Artificial intelligence in drug discovery and development. Drug Discovery Today, 2021; 26: 80–93.
2. Xu, Y. et al. Artificial intelligence: A powerful paradigm for scientific research. The Innovation, 2021; 2: 100179.
3. Zhuang, D. & Ibrahim, A. K. Deep learning for drug discovery: A study of identifying high efficacy drug compounds using a cascade transfer learning approach. Appl. Sci., 2021; 11: 7772.
4. Pu, L. et al. EToxPred: A machine learning-based approach to estimate the toxicity of drug candidates 11 Medical and Health Sciences 1115 Pharmacology and Pharmaceutical Sciences 03 Chemical Sciences 0305 Organic Chemistry 03 Chemical Sciences 0304 Medicinal and Biomol. BMC Pharmacol. Toxicol, 2019; 20: 1–15.
5. Rees, C. The Ethics of Artificial Intelligence. in IFIP Advances in Information and Communication Technology, 2020; 555: 55–69. (Chapman and Hall/CRC).
6. Wess, G., Urmann, M. & Sickenberger, B. Medicinal Chemistry: Challenges and Opportunities. Angew. Chem. Int. Ed., 2001; 40.
7. Chen, R., Liu, X., Jin, S., Lin, J. & Liu, J. Machine learning for drug-target interaction prediction. Molecules, 2018; 23: 2208.
8. Cerchia, C.; Lavecchia, A. New avenues in artificial-intelligenceassisted drug discovery. Drug Discov. Today, 2023; 28(4): 103516. [http://dx.doi.org/10.1016/j.drudis.2023.103516] [PMID: 36736583]
9. Trenfield, S.J.; Awad, A.; McCoubrey, L.E.; Elbadawi, M.; Goyanes, A.; Gaisford, S.; Basit, A.W. Advancing pharmacy and healthcare with virtual digital technologies. Adv. Drug Deliv. Rev., 2022; 182: 114098. [http://dx.doi.org/10.1016/j.addr.2021.114098] [PMID: 34998901]
10. Dara, S.; Dhamercherla, S.; Jadav, S.S.; Babu, C.H.M.; Ahsan, M.J. Machine learning in drug discovery: A review. Artif. Intell. Rev., 2022; 55(3): 1947-1999. [http://dx.doi.org/10.1007/s10462-021-10058-4] [PMID: 34393317]
11. Vora, L.K.; Gholap, A.D.; Jetha, K.; Thakur, R.R.S.; Solanki, H.K.; Chavda, V.P. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics, 2023; 15(7): 1916. [http://dx.doi.org/10.3390/pharmaceutics15071916] [PMID: 37514102]
12. Gupta, R.; Srivastava, D.; Sahu, M.; Tiwari, S.; Ambasta, R.K.; Kumar, P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol. Divers., 2021; 25(3): 1315-1360. [http://dx.doi.org/10.1007/s11030-021-10217-3] [PMID: 33844136]
13. Nayarisseri, A.; Khandelwal, R.; Tanwar, P.; Madhavi, M.; Sharma, D.; Thakur, G.; Speck-Planche, A.; Singh, S.K. Artificial intelligence, big data and machine learning approaches in precision medicine & drug discovery. Curr. Drug Targets, 2021; 22(6): 631-655. [http://dx.doi.org/10.2174/18735592MTEzsMDMnz] [PMID: 33397265
14. Selvaraj, C.; Chandra, I.; Singh, S.K. Artificial intelligence and machine learning approaches for drug design: Challenges and opportunities for the pharmaceutical industries. Mol. Divers., 2021; 1-21. [PMID: 34686947]
15. Lu, M.; Yin, J.; Zhu, Q.; Lin, G.; Mou, M.; Liu, F.; Pan, Z.; You, N.; Lian, X.; Li, F.; Zhang, H.; Zheng, L.; Zhang, W.; Zhang, H.; Shen, Z.; Gu, Z.; Li, H.; Zhu, F. Artificial intelligence in pharmaceutical sciences. Engineering, 2023; 27: 37-69. [http://dx.doi.org/10.1016/j.eng.2023.01.014]
16. Paul, S.M.; Mytelka, D.S.; Dunwiddie, C.T.; Persinger, C.C.; Munos, B.H.; Lindborg, S.R.;

Schacht, A.L. How to improve R and D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov., 2010; 9(3): 203-214.
17. Troiano, G.; Nolan, J.; Parsons, D.; Van Geen Hoven, C.; Zale, S. A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products. AAPS J., 2016; 18: 1354–1365. [CrossRef] [PubMed]
18. Puri, M.; Pathak, Y.; Sutariya, V.K.; Tipparaju, S.; Moreno, W. Artificial Neural Network for Drug Design, Delivery and Disposition; Academic Press: Cambridge, MA, USA, 2015.
19. Vyas, M.; Thakur, S.; Riyaz, B.; Bansal, K.; Tomar, B.; Mishra, V. Artificial Intelligence: The Beginning of a New Era in Pharmacy Profession. Asian J. Pharm., 2018; 12: 72–76.
20. Hassanzadeh, P.; Atyabi, F.; Dinarvand, R. The Significance of Artificial Intelligence in Drug Delivery System Design. Adv. Drug Deliv. Rev., 2019; 151–152: 169–190. [CrossRef]
21. Chavda, V.; Bezbaruah, R.; Valu, D.; Desai, S.; Chauhan, N.; Marwadi, S.; Deka, G.; Ding, Z. Clinical Applications of "Omics" Technology as a Bioinformatic Tool. In Bioinformatics Tools for Pharmaceutical Drug Product Development; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2023; 117–145.
22. Sacha, G.M.; Varona, P. Artificial Intelligence in Nanotechnology. Nanotechnology, 2013; 24: 452002.
23. Weng, H.; Liu, Z.; Yan, S.; Fan, M.; Ou, A.; Chen, D.; Hao, T. A framework for automated knowledge graph construction towards traditional Chinese medicine. Health Information Science: 6th International Conference., October 7-9, 2017, Moscow, Russia, 170-181.
24. Ruan, C; Ma, J; Wang, Y; Zhang, Y; Yang, Y; Kraus, S. Discovering regularities from traditional chinese medicine prescriptions via bipartite embedding model. IJCAI, 2019; 2019: 1-7.
25. Wang, Y.; Jafari, M.; Tang, Y.; Tang, J. Predicting Meridian in Chinese traditional medicine using machine learning approaches. PLOS Comput. Biol., 2019; 15(11): e1007249. [http://dx.doi.org/10.1371/journal.pcbi.1007249] [PMID: 31765369]
26. Selvaraj, G.; Kaliamurthi, S.; Peslherbe, G.H.; Wei, D.Q. Application of artificial intelligence in drug repurposing: A mini-review. Curr. Chinese Sci., 2021; 1(3): 333-345. [http://dx.doi.org/10.2174/2210298101666210204162006]
27. Paul, D.; Sanap, G.; Shenoy, S.; Kalyane, D.; Kalia, K.; Tekade, R.K. Artificial intelligence in drug discovery and development. Drug Discov. Today, 2021; 26(1): 80-93. [http://dx.doi.org/10.1016/j.drudis.2020.10.010] [PMID: 33099022]
28. Ramesh, A.N.; Kambhampati, C.; Monson, J.R.T.; Drew, P.J. Artificial intelligence in medicine. Ann. R. Coll. Surg. Engl., 2004; 86(5): 334-338. [http://dx.doi.org/10.1308/147870804290] [PMID: 15333167]
29. Miles, J.C.; Walker, A.J. The potential application of artificial intelligence in transport. IEE Proceed. Intel. Transp. Sys., 2006; 153(3): 183-198.
30. Duch, W.; Swaminathan, K.; Meller, J. Artificial intelligence approaches for rational drug design and discovery. Curr. Pharm. Des., 2007; 13(14): 1497-1508. [http://dx.doi.org/10.2174/138161207780765954] [PMID: 17504169]
31. Blasiak, A.; Khong, J.; Kee, T. CURATE. AI: Optimizing personalized medicine with artificial intelligence. SLAS Technol., 2020; 25(2): 95-105. [http://dx.doi.org/10.1177/2472630319890316] [PMID: 31771394]
32. Gurung, A.B.; Ali, M.A.; Lee, J.; Farah, M.A.; Al-Anazi, K.M. An updated review of computer-aided drug design and its application to COVID-19. BioMed Res. Int., 2021; 2021: 1-18. [http://dx.doi.org/10.1155/2021/8853056] [PMID: 34258282]
33. Song, C.M.; Lim, S.J.; Tong, J.C. Recent advances in computer-aided drug design. Brief. Bioinform., 2009; 10(5): 579-591. [http://dx.doi.org/10.1093/bib/bbp023] [PMID: 19433475]
34. DiMasi, J.A.; Grabowski, H.G.; Hansen, R.W. Innovation in the pharmaceutical industry: New estimates of R and D costs. J. Health Econ., 2016; 47: 20-33. [http://dx.doi.org/10.1016/j.jhealeco.2016.01.012] [PMID: 26928437]
35. Macalino, S.J.Y.; Gosu, V.; Hong, S.; Choi, S. Role of computer aided drug design in modern drug discovery. Arch. Pharm. Res., 2015; 38(9): 1686-1701. [http://dx.doi.org/10.1007/s12272-015-0640-5] [PMID: 26208641]
36. Raza, M.A.; Aziz, S.; Noreen, M.; Saeed, A.; Anjum, I.; Ahmed, M.; Raza, S.M. Artificial intelligence (AI) in pharmacy: An overview of innovations. Innov. Pharm., 2022; 13(2): 13. [http://dx.doi.org/10.24926/iip.v13i2.4839] [PMID: 36654703]
37. Khan, O.; Parvez, M.; Kumari, P.; Parvez, S.; Ahmad, S. The future of pharmacy: How AI is revolutionizing the industry. Intel. Pharm., 2023; 1(1): 32-40. [http://dx.doi.org/10.1016/j.ipha.2023.04.008]
38. Patil, P.; Nrip, N.; Hajare, A.; Hajare, D.; Patil, M.; Kanthe, R.; Gaikwad, A.; Vidyapeeth, B. Artificial intelligence and tools in pharmaceuticals: An overview. Res. J. Pharm. Technol., 2023; 16(4): 2075-2082. [http://dx.doi.org/10.1080/13696998.2023.2265245]
39. Jarab, A.S.; Abu Heshmeh, S.R.; Al Meslamani, A.Z. Artificial intelligence (AI) in pharmacy: An

overview of innovations. J. Med. Econ., 2023; 26(1): 1261-1265. [http://dx.doi.org/10.1080/13696998.2023.2265245] [PMID: 37772743]

40. Gómez-Bombarelli, R.; Wei, J.N.; Duvenaud, D.; Hernández-Lobato, J.M.; Sánchez-Lengeling, B.; Sheberla, D.; Aguilera-Iparraguirre, J.; Hirzel, T.D.; Adams, R.P.; Aspuru-Guzik, A. Automatic chemical design using a data-driven continuous representation of molecules. ACS Cent. Sci., 2018; 4(2): 268-276. [http://dx.doi.org/10.1021/acscentsci.7b00572] [PMID: 29532027]
41. Jin, W.; Yang, K.; Barzilay, R.; Jaakkola, T Learning multimodal graph-to-graph translation for molecular optimization arXiv:1812.01070, 2018. [http://dx.doi.org/10.48550/arXiv.1812.01070]
42. Shi, C.; Xu, M.; Zhu, Z.; Zhang, W.; Zhang, M.; Tang, J Graphaf: a flow-based autoregressive model for molecular graph generation. arXiv:2001.09382, 2020.
43. Zang, C.; Wang, F. MoFlow: An Invertible Flow Model for Generating Molecular Graphs. KDD '20: Proceedings of the 26th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining., August 23–27, 2020; USA, 1-10. [http://dx.doi.org/10.1145/3394486.3403104]
44. Jin, W; Barzilay, R; Jaakkola, T Multi-objective molecule generation using interpretable substructures. arXiv:2002.03244, 2020.
45. Bung, N.; Krishnan, S.R.; Bulusu, G.; Roy, A. De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence. Future Med. Chem., 2021; 13(6): 575-585. [http://dx.doi.org/10.4155/fmc-2020-0262] [PMID: 33590764]
46. Weng, H.; Liu, Z.; Yan, S.; Fan, M.; Ou, A.; Chen, D.; Hao, T. A framework for automated knowledge graph construction towards traditional Chinese medicine. Health Information Science: 6th International Conference., October 7-9, Moscow, Russia, 2017; 170-181.
47. Ruan, C; Ma, J; Wang, Y; Zhang, Y; Yang, Y; Kraus, S. Discovering regularities from traditional chinese medicine prescriptions via bipartite embedding model. IJCAI, 2019; 2019: 1-7. [http://dx.doi.org/10.24963/ijcai.2019/464]
48. Wang, Y.; Jafari, M.; Tang, Y.; Tang, J. Predicting Meridian in Chinese traditional medicine using machine learning approaches. PLOS Comput. Biol., 2019; 15(11): e1007249. [http://dx.doi.org/10.1371/journal.pcbi.1007249] [PMID: 31765369]
49. Selvaraj, G.; Kaliamurthi, S.; Peslherbe, G.H.; Wei, D.Q. Application of artificial intelligence in drug repurposing: A mini-review. Curr. Chinese Sci., 2021; 1(3): 333-345. [http://dx.doi.org/10.2174/2210298101666210204162006].